Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

249.30DKK
24 Feb 2017
Change (% chg)

kr.0.50 (+0.20%)
Prev Close
kr.248.80
Open
kr.251.00
Day's High
kr.251.00
Day's Low
kr.248.00
Volume
3,262,422
Avg. Vol
4,262,188
52-wk High
kr.391.30
52-wk Low
kr.218.20

NOVOb.CO

Chart for NOVOb.CO

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 1.41
Market Cap(Mil.): kr.501,732.19
Shares Outstanding(Mil.): 2,012.56
Dividend: 4.60
Yield (%): 3.05

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 16.66 28.84 29.63
EPS (TTM): 14.96 -- --
ROI: 75.08 13.44 12.96
ROE: 82.23 14.34 14.11

BRIEF-Novo Nordisk proposes Novo A/S CEO and former BG chief as board members

* Says the board of directors proposes election of Kasim Kutay and Helge Lund as new members of the board of directors at the annual general meeting

Feb 24 2017

European shares fall weighed down by poor earnings; Reckitt up

* Novo Nordisk, Deutsche Bank among top losers after poor results

Feb 02 2017

Drugmaker Novo Nordisk cautious over unpredictable U.S. politics

COPENHAGEN Novo Nordisk shares took another hit on Thursday as the world's top maker of diabetes drugs disappointed investors with a lower 2017 sales and profit growth forecast due to price pressure and U.S. political uncertainty.

Feb 02 2017

UPDATE 2-Drugmaker Novo Nordisk cautious over unpredictable U.S. politics

COPENHAGEN, Feb 2 Novo Nordisk shares took another hit on Thursday as the world's top maker of diabetes drugs disappointed investors with a lower 2017 sales and profit growth forecast due to price pressure and U.S. political uncertainty.

Feb 02 2017

European shares edge lower on disappointing company updates

LONDON, Feb 2 European shares fell on Thursday after disappointing company updates, with Denmark's Novo Nordisk leading the market down and Finnish retailer Kesko weakening on lower-than-expected sales.

Feb 02 2017

BRIEF-Novo Nordisk CEO: We are not concerned about Trump

Feb 2 Drugmaker Novo Nordisk CEO Lars Fruergaard Jorgensen made the following comments during a call with journalists:

Feb 02 2017

Drugmaker Novo Nordisk lowers 2017 sales, profit outlook

COPENHAGEN, Feb 2 Denmark's Novo Nordisk , the world's top maker of diabetes drugs, said fourth-quarter operating profit came in a touch below forecasts and lowered its 2017 operating profit and sales growth outlook measured in local currency terms.

Feb 02 2017

BRIEF-Novo Nordisk cuts 2017 sales, profit outlook in local currencies

* Says 2017 sales growth is expected to be in the range of a decline of 1 percent to a growth of 4 percent measured in local currencies

Feb 02 2017

Stock futures signal slightly higher market open. For more see the European equities LiveMarkets blog

LONDON, Jan 31 Live coverage of European markets now available on cpurl://apps.cp./cms/?pageId=livemarkets

Jan 31 2017

Sanofi, Novo Nordisk and Lilly named in patients' price fixing suit

NEW YORK Three of the biggest makers of diabetes treatments, Sanofi SA, Novo Nordisk and Eli Lilly and Co, were named in a class action lawsuit about price fixing filed by a group of patients.

Jan 30 2017

More From Around the Web

Earnings vs. Estimates